



APPENDICES TABLE OF CONTENTS

E-mail comments regarding the content of the CIBMTR Forms Instruction Manual to: CIBMTRFormsManualComments@nmdp.org. Comments will be considered for future manual updates and revisions. For questions that require an immediate response, please contact your transplant center's CIBMTR CRC.

- A. [Abbreviations](#)
- B. [Glossary of Terms](#)
- C. [CIBMTR Data Collection Forms](#)
- D. [Unique ID Assignment Form \(CRID\) Form 2804](#)
- E. [Public Health Authority \(PHA\) Status](#)
- F. [Validation Ranges](#)
- G. [Continuous Process Improvement \(CPI\) and Procedures for Non-Compliance](#)
- H. [Summary of CIBMTR On-Site Audit Program](#)
- I. [Ethnicity and Race](#)
- J. [CIBMTR Contact Information](#)
- K. [Key Fields](#)
- L. [Karnofsky/Lansky Performance Status](#)
- M. [The Hematopoietic Cell Transplant Co-Morbidity Index \(HCT-CI\)](#)
- N. [Response Evaluation Criteria in Solid Tumors \(RECIST\)](#)
- O. [How to Distinguish Infusion Types](#)
- P. [Definition of Product](#)
- Q. [United States Abbreviations](#)
- R. [Cytogenetic Abbreviations and Terminology](#)
- S. [Multiple Donor Chimerism](#)
- T. [Pre-HCT Treatments for Lymphoma](#)
- U. [Helpful Hints for Reporting Co-Existing Diseases](#)
- V. [Multiple Myeloma – Defining What Baseline to Use When Determining the Best Response to HSCT](#)
- W. [Tracking Disease Status for Multiple Myeloma](#)
- X. *Coming Soon!*
- Y. [Critical Fields](#)
- Z. [Primary Disease and Disease Inserts Due](#)